Angiocidin Inhibitory Peptides Decrease Tumor Burden in a Murine Colon Cancer Model

Catherine Liebig, Neeti Agarwal, Gustavo E. Ayala, Gordana Verstovsek, George P. Tuszynski, Daniel Albo

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Introduction: We have recently developed two inhibitory peptides that target angiocidin, a key mediator of tumor progression and angiogenesis. In this study, we investigate the expression of angiocidin in human colon cancer specimens and evaluate the therapeutic efficacy of our angiocidin inhibitory peptides. Methods: We created a colon cancer tissue array containing primary tumor, normal colon, negative and positive lymph nodes, and liver metastases (when available) from 159 consecutive colon cancer specimens. Angiocidin expression was determined by immunohistochemistry. The efficacy of 6-mer and 25-mer angiocidin inhibitory peptides was determined in a murine model of human colon cancer. Treatment efficacy was based on primary tumor volume and measures of tumor burden, including internal disease score and health score. Western blots were used to determine angiocidin expression in xenografts. Results: Eighty-nine percent of primary tumors and 91% of positive lymph nodes expressed angiocidin. Normal colon was negative in 94% of specimens, and normal lymph nodes were negative or weakly positive in 79% of specimens. All liver metastases were positive for angiocidin. Animals in both peptide treatment groups showed improvement in health score and internal disease score compared with control animals (P = 0.001). Treatment with 6-mer and 25-mer peptide resulted in 3-fold and 16-fold reductions, respectively, in primary tumor volume (P = 0.001). Angiocidin expression in primary tumors of peptide-treated mice correlated with tumor burden (P < 0.05). Conclusions: Angiocidin is overexpressed in human colon cancer specimens. Angiocidin-inhibitory peptides are well tolerated in vivo and effectively reduce primary tumor volume and tumor burden in human colon cancer xenografts.

Original languageEnglish (US)
Pages (from-to)320-326
Number of pages7
JournalJournal of Surgical Research
Volume142
Issue number2
DOIs
StatePublished - Oct 1 2007
Externally publishedYes

Fingerprint

Tumor Burden
Colonic Neoplasms
Peptides
Lymph Nodes
Heterografts
Neoplasms
Colon
Neoplasm Metastasis
Liver
Health
Therapeutics
Western Blotting
Immunohistochemistry

Keywords

  • angiocidin
  • angiocidin-inhibitory peptide
  • colon cancer
  • CSVTCG
  • nude mouse model
  • peptide therapy
  • tissue array
  • tumor burden
  • xenograft model

ASJC Scopus subject areas

  • Surgery

Cite this

Angiocidin Inhibitory Peptides Decrease Tumor Burden in a Murine Colon Cancer Model. / Liebig, Catherine; Agarwal, Neeti; Ayala, Gustavo E.; Verstovsek, Gordana; Tuszynski, George P.; Albo, Daniel.

In: Journal of Surgical Research, Vol. 142, No. 2, 01.10.2007, p. 320-326.

Research output: Contribution to journalArticle

Liebig, Catherine ; Agarwal, Neeti ; Ayala, Gustavo E. ; Verstovsek, Gordana ; Tuszynski, George P. ; Albo, Daniel. / Angiocidin Inhibitory Peptides Decrease Tumor Burden in a Murine Colon Cancer Model. In: Journal of Surgical Research. 2007 ; Vol. 142, No. 2. pp. 320-326.
@article{4783526725dc4bb8bcfaa2312b523800,
title = "Angiocidin Inhibitory Peptides Decrease Tumor Burden in a Murine Colon Cancer Model",
abstract = "Introduction: We have recently developed two inhibitory peptides that target angiocidin, a key mediator of tumor progression and angiogenesis. In this study, we investigate the expression of angiocidin in human colon cancer specimens and evaluate the therapeutic efficacy of our angiocidin inhibitory peptides. Methods: We created a colon cancer tissue array containing primary tumor, normal colon, negative and positive lymph nodes, and liver metastases (when available) from 159 consecutive colon cancer specimens. Angiocidin expression was determined by immunohistochemistry. The efficacy of 6-mer and 25-mer angiocidin inhibitory peptides was determined in a murine model of human colon cancer. Treatment efficacy was based on primary tumor volume and measures of tumor burden, including internal disease score and health score. Western blots were used to determine angiocidin expression in xenografts. Results: Eighty-nine percent of primary tumors and 91{\%} of positive lymph nodes expressed angiocidin. Normal colon was negative in 94{\%} of specimens, and normal lymph nodes were negative or weakly positive in 79{\%} of specimens. All liver metastases were positive for angiocidin. Animals in both peptide treatment groups showed improvement in health score and internal disease score compared with control animals (P = 0.001). Treatment with 6-mer and 25-mer peptide resulted in 3-fold and 16-fold reductions, respectively, in primary tumor volume (P = 0.001). Angiocidin expression in primary tumors of peptide-treated mice correlated with tumor burden (P < 0.05). Conclusions: Angiocidin is overexpressed in human colon cancer specimens. Angiocidin-inhibitory peptides are well tolerated in vivo and effectively reduce primary tumor volume and tumor burden in human colon cancer xenografts.",
keywords = "angiocidin, angiocidin-inhibitory peptide, colon cancer, CSVTCG, nude mouse model, peptide therapy, tissue array, tumor burden, xenograft model",
author = "Catherine Liebig and Neeti Agarwal and Ayala, {Gustavo E.} and Gordana Verstovsek and Tuszynski, {George P.} and Daniel Albo",
year = "2007",
month = "10",
day = "1",
doi = "10.1016/j.jss.2007.02.036",
language = "English (US)",
volume = "142",
pages = "320--326",
journal = "Journal of Surgical Research",
issn = "0022-4804",
publisher = "Academic Press Inc.",
number = "2",

}

TY - JOUR

T1 - Angiocidin Inhibitory Peptides Decrease Tumor Burden in a Murine Colon Cancer Model

AU - Liebig, Catherine

AU - Agarwal, Neeti

AU - Ayala, Gustavo E.

AU - Verstovsek, Gordana

AU - Tuszynski, George P.

AU - Albo, Daniel

PY - 2007/10/1

Y1 - 2007/10/1

N2 - Introduction: We have recently developed two inhibitory peptides that target angiocidin, a key mediator of tumor progression and angiogenesis. In this study, we investigate the expression of angiocidin in human colon cancer specimens and evaluate the therapeutic efficacy of our angiocidin inhibitory peptides. Methods: We created a colon cancer tissue array containing primary tumor, normal colon, negative and positive lymph nodes, and liver metastases (when available) from 159 consecutive colon cancer specimens. Angiocidin expression was determined by immunohistochemistry. The efficacy of 6-mer and 25-mer angiocidin inhibitory peptides was determined in a murine model of human colon cancer. Treatment efficacy was based on primary tumor volume and measures of tumor burden, including internal disease score and health score. Western blots were used to determine angiocidin expression in xenografts. Results: Eighty-nine percent of primary tumors and 91% of positive lymph nodes expressed angiocidin. Normal colon was negative in 94% of specimens, and normal lymph nodes were negative or weakly positive in 79% of specimens. All liver metastases were positive for angiocidin. Animals in both peptide treatment groups showed improvement in health score and internal disease score compared with control animals (P = 0.001). Treatment with 6-mer and 25-mer peptide resulted in 3-fold and 16-fold reductions, respectively, in primary tumor volume (P = 0.001). Angiocidin expression in primary tumors of peptide-treated mice correlated with tumor burden (P < 0.05). Conclusions: Angiocidin is overexpressed in human colon cancer specimens. Angiocidin-inhibitory peptides are well tolerated in vivo and effectively reduce primary tumor volume and tumor burden in human colon cancer xenografts.

AB - Introduction: We have recently developed two inhibitory peptides that target angiocidin, a key mediator of tumor progression and angiogenesis. In this study, we investigate the expression of angiocidin in human colon cancer specimens and evaluate the therapeutic efficacy of our angiocidin inhibitory peptides. Methods: We created a colon cancer tissue array containing primary tumor, normal colon, negative and positive lymph nodes, and liver metastases (when available) from 159 consecutive colon cancer specimens. Angiocidin expression was determined by immunohistochemistry. The efficacy of 6-mer and 25-mer angiocidin inhibitory peptides was determined in a murine model of human colon cancer. Treatment efficacy was based on primary tumor volume and measures of tumor burden, including internal disease score and health score. Western blots were used to determine angiocidin expression in xenografts. Results: Eighty-nine percent of primary tumors and 91% of positive lymph nodes expressed angiocidin. Normal colon was negative in 94% of specimens, and normal lymph nodes were negative or weakly positive in 79% of specimens. All liver metastases were positive for angiocidin. Animals in both peptide treatment groups showed improvement in health score and internal disease score compared with control animals (P = 0.001). Treatment with 6-mer and 25-mer peptide resulted in 3-fold and 16-fold reductions, respectively, in primary tumor volume (P = 0.001). Angiocidin expression in primary tumors of peptide-treated mice correlated with tumor burden (P < 0.05). Conclusions: Angiocidin is overexpressed in human colon cancer specimens. Angiocidin-inhibitory peptides are well tolerated in vivo and effectively reduce primary tumor volume and tumor burden in human colon cancer xenografts.

KW - angiocidin

KW - angiocidin-inhibitory peptide

KW - colon cancer

KW - CSVTCG

KW - nude mouse model

KW - peptide therapy

KW - tissue array

KW - tumor burden

KW - xenograft model

UR - http://www.scopus.com/inward/record.url?scp=34548674008&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34548674008&partnerID=8YFLogxK

U2 - 10.1016/j.jss.2007.02.036

DO - 10.1016/j.jss.2007.02.036

M3 - Article

C2 - 17719063

AN - SCOPUS:34548674008

VL - 142

SP - 320

EP - 326

JO - Journal of Surgical Research

JF - Journal of Surgical Research

SN - 0022-4804

IS - 2

ER -